Octagon Capital Advisors’s Regulus Therapeutics RGLS Stock Holding History

Octagon Capital Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,637,076	Closed	-$8.11M	–	33
2025 Q1	$8.11M	Sell	4,637,076 -211,726	-4%	-$279K	1.57%	24
2024 Q4	$7.66M	Buy	4,848,802 +585,101	+14%	+$899K	1.26%	25
2024 Q3	$6.69M	Hold	4,263,701	–	–	1.04%	25
2024 Q2	$7.61M	Buy	+4,263,701	New	+$9.9M	1.2%	23

Other funds holding RGLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Octagon Capital Advisors's RGLS Position: Q2 2025 in Review

Octagon Capital Advisors sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 4,637,076 shares — an estimated $8.11M sold.

Octagon Capital Advisors first reported a position in RGLS in Q2 2024 and held it in 4 quarters. The position peaked at $8.11M in Q1 2025. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

Octagon Capital Advisors reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
Octagon Capital Advisors sold 4,637,076 Regulus Therapeutics shares in Q2 2025, an estimated $8.11M.
Octagon Capital Advisors first reported a position in Regulus Therapeutics in Q2 2024 and held it in 4 quarters.
Octagon Capital Advisors's Regulus Therapeutics position peaked at $8.11M in Q1 2025.
0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on Octagon Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.